Science337d left
When will the FDA approve Intellia Therapeutics' lonvo-z?
Make a prediction
Resolution
Criteria
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.
Source
Kalshi (kalshi.com)
Recent News
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics
Intellia Therapeutics
- Intellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment - Fierce Biotech
Fierce Biotech
- Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter
The Pharma Letter
Closes 337d left
Resolves Jan 1, 2028, 3:00 PM UTC
Discussion
Sign in to join the discussion.